Group 1 - Halozyme Therapeutics, Inc. (NASDAQ:HALO) is considered one of the best biotech stocks to buy, with Benchmark maintaining a Buy rating and increasing the price target from $75 to $90 due to favorable financial forecasts and solid earnings results for the first half of 2025 [1][2] - Benchmark's revised price target is based on the expectation that Halozyme's projected 2025 revenues will be 8.5 times higher, highlighting the company's growth potential [2] - The FDA recently approved Merck's Keytruda Qlex, which utilizes an enzyme licensed from Alteogen that competes with Halozyme's Enhanze enzyme, leading to ongoing patent disputes between the two companies [2][3] Group 2 - Halozyme Therapeutics operates as a biopharmaceutical technology platform company, focusing on creating, manufacturing, and selling drug-device combination solutions using advanced auto-injector technologies [3]
Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target